Urinary and plasma levels of vasohibin-1 can predict renal functional deterioration in patients with renal disorders

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Hinamoto, Norikazu ^a   Maeshima, Yohei ^a   Saito, Daisuke ^a   Yamasaki, Hiroko ^a   Tanabe, Katsuyuki ^a   Nasu, Tatsuyo ^a   Watatani, Hiroyuki ^a   Ujike, Haruyo ^a   Kinomura, Masaru ^a   Sugiyama, Hitoshi ^a   Sonoda, Hikaru ^b   Sato, Yasufumi ^c   Makino, Hirofumi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b SHIONOGI AND CO LTD   (Japan)

^c TOHOKU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

REGULATOR PROTEIN; UNCLASSIFIED DRUG; VASOHIBIN 1; BIOLOGICAL MARKER; CELL CYCLE PROTEIN; VASH1 PROTEIN, HUMAN;

ADULT; AGE; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; FEMALE; FUNCTIONAL ASSESSMENT; HOSPITAL PATIENT; HUMAN; HUMAN TISSUE; JAPANESE (PEOPLE); KIDNEY BIOPSY; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTION; PREDICTIVE VALUE; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN URINE LEVEL; REFERENCE VALUE; SYSTOLIC BLOOD PRESSURE; VASOHIBIN 1 BLOOD LEVEL; VASOHIBIN 1 URINE LEVEL; ADOLESCENT; BLOOD; CASE CONTROL STUDY; CHRONIC KIDNEY FAILURE; MIDDLE AGED; PATHOLOGY; URINE; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CELL CYCLE PROTEINS; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED;

EID: 84902590702     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0096932     Document Type: Article

References (50)

1. Nasu T, Kinomura M, Tanabe K, Yamasaki H, Htay SL, et al. (2012) Sustained-release prostacyclin analog ONO-1301 ameliorates tubulointerstitial alterations in a mouse obstructive nephropathy model. Am J Physiol Renal Physiol 302: F1616-1629.
2. Thorner PS, Ho M, Eremina V, Sado Y, Quaggin S (2008) Podocytes contribute to the formation of glomerular crescents. J Am Soc Nephrol 19: 495-502. (Pubitemid 351355393)
3. Lemley KV, Lafayette RA, Safai M, Derby G, Blouch K, et al. (2002) Podocytopenia and disease severity in IgA nephropathy. Kidney Int 61: 1475-1485. (Pubitemid 34304509)
4. Macconi D, Bonomelli M, Benigni A, Plati T, Sangalli F, et al. (2006) Pathophysiologic implications of reduced podocyte number in a rat model of progressive glomerular injury. Am J Pathol 168: 42-54. (Pubitemid 43062558)
5. Wang G, Lai FM, Kwan BC, Lai KB, Chow KM, et al. (2009) Podocyte loss in human hypertensive nephrosclerosis. Am J Hypertens 22: 300-306.
6. Kang DH, Hughes J, Mazzali M, Schreiner GF, Johnson RJ (2001) Impaired angiogenesis in the remnant kidney model: II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function. J Am Soc Nephrol 12: 1448-1457. (Pubitemid 32666327)
7. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, et al. (1996) Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380: 439-442. (Pubitemid 26102720)
8. Watanabe K, Hasegawa Y, Yamashita H, Shimizu K, Ding Y, et al. (2004) Vasohibin as an endothelium-derived negative feedback regulator of angiogenesis. J Clin Invest 114: 898-907. (Pubitemid 39578717)
9. Miyashita H, Watanabe T, Hayashi H, Suzuki Y, Nakamura T, et al. (2012) Angiogenesis inhibitor vasohibin-1 enhances stress resistance of endothelial cells via induction of SOD2 and SIRT1. PLoS One 7: e46459.
10. Suzuki Y, Kobayashi M, Miyashita H, Ohta H, Sonoda H, et al. (2010) Isolation of a small vasohibin-binding protein (SVBP) and its role in vasohibin secretion. J Cell Sci 123: 3094-3101.
11. Shen J, Yang X, Xiao WH, Hackett SF, Sato Y, et al. (2006) Vasohibin is upregulated by VEGF in the retina and suppresses VEGF receptor 2 and retinal neovascularization. Faseb J 20: 723-725. (Pubitemid 46671194)
12. Yamashita H, Abe M, Watanabe K, Shimizu K, Moriya T, et al. (2006) Vasohibin prevents arterial neointimal formation through angiogenesis inhibition. Biochem Biophys Res Commun 345: 919-925. (Pubitemid 43776484)
13. Nasu T, Maeshima Y, Kinomura M, Hirokoshi-Kawahara K, Tanabe K, et al. (2009) Vasohibin-1, a negative feedback regulator of angiogenesis, ameliorates renal alterations in a mouse model of diabetic nephropathy. Diabetes 58: 2365-2375.
14. Saito D, Maeshima Y, Nasu T, Yamasaki H, Tanabe K, et al. (2011) Amelioration of renal alterations in obese type 2 diabetic mice by vasohibin-1, a negative feedback regulator of angiogenesis. Am J Physiol Renal Physiol 300: F873-886.
15. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31.
16. Kitamoto Y, Tokunaga H, Tomita K (1997) Vascular endothelial growth factor is an essential molecule for mouse kidney development: glomerulogenesis and nephrogenesis. J Clin Invest 99: 2351-2357. (Pubitemid 27227711)
17. Tufro A, Norwood VF, Carey RM, Gomez RA (1999) Vascular endothelial growth factor induces nephrogenesis and vasculogenesis. J Am Soc Nephrol 10: 2125-2134. (Pubitemid 29453490)
18. Woolf AS, Yuan HT (2001) Angiopoietin growth factors and Tie receptor tyrosine kinases in renal vascular development. Pediatr Nephrol 16: 177-184. (Pubitemid 32125170)
19. Hara A, Wada T, Furuichi K, Sakai N, Kawachi H, et al. (2006) Blockade of VEGF accelerates proteinuria, via decrease in nephrin expression in rat crescentic glomerulonephritis. Kidney Int 69: 1986-1995. (Pubitemid 43924262)
20. Kang DH, Anderson S, Kim YG, Mazzalli M, Suga S, et al. (2001) Impaired angiogenesis in the aging kidney: vascular endothelial growth factor and thrombospondin-1 in renal disease. Am J Kidney Dis 37: 601-611. (Pubitemid 32195301)
21. Kang DH, Joly AH, Oh SW, Hugo C, Kerjaschki D, et al. (2001) Impaired angiogenesis in the remnant kidney model: I. Potential role of vascular endothelial growth factor and thrombospondin-1. J Am Soc Nephrol 12: 1434-1447. (Pubitemid 32666326)
22. Cooper ME, Vranes D, Youssef S, Stacker SA, Cox AJ, et al. (1999) Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes 48: 2229-2239. (Pubitemid 29521855)
23. Long DA, Woolf AS, Suda T, Yuan HT (2001) Increased renal angiopoietin-1 expression in folic acid-induced nephrotoxicity in mice. J Am Soc Nephrol 12: 2721-2731. (Pubitemid 33115419)
24. Yuan HT, Tipping PG, Li XZ, Long DA, Woolf AS (2002) Angiopoietin correlates with glomerular capillary loss in anti-glomerular basement membrane glomerulonephritis. Kidney Int 61: 2078-2089. (Pubitemid 34539325)
25. Rizkalla B, Forbes JM, Cao Z, Boner G, Cooper ME (2005) Temporal renal expression of angiogenic growth factors and their receptors in experimental diabetes: role of the renin-angiotensin system. J Hypertens 23: 153-164. (Pubitemid 40128994)
26. Masuda Y, Shimizu A, Mori T, Ishiwata T, Kitamura H, et al. (2001) Vascular endothelial growth factor enhances glomerular capillary repair and accelerates resolution of experimentally induced glomerulonephritis. Am J Pathol 159: 599-608. (Pubitemid 32751090)
27. Shimizu A, Masuda Y, Mori T, Kitamura H, Ishizaki M, et al. (2004) Vascular endothelial growth factor165 resolves glomerular inflammation and accelerates glomerular capillary repair in rat anti-glomerular basement membrane glomerulonephritis. J Am Soc Nephrol 15: 2655-2665. (Pubitemid 41103372)
28. Ostendorf T, Kunter U, Eitner F, Loos A, Regele H, et al. (1999) VEGF(165) mediates glomerular endothelial repair. J Clin Invest 104: 913-923. (Pubitemid 29536341)
29. Kim YG, Suga SI, Kang DH, Jefferson JA, Mazzali M, et al. (2000) Vascular endothelial growth factor accelerates renal recovery in experimental thrombotic microangiopathy. Kidney Int 58: 2390-2399.
30. de Vriese AS, Tilton RG, Elger M, Stephan CC, Kriz W, et al. (2001) Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 12: 993-1000.
31. Flyvbjerg A, Dagnaes-Hansen F, De Vriese AS, Schrijvers BF, Tilton RG, et al. (2002) Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes 51: 3090-3094.
32. Sung SH, Ziyadeh FN, Wang A, Pyagay PE, Kanwar YS, et al. (2006) Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice. J Am Soc Nephrol 17: 3093-3104. (Pubitemid 44707769)
33. Kim W, Moon SO, Lee SY, Jang KY, Cho CH, et al. (2006) COMP-angiopoietin-1 ameliorates renal fibrosis in a unilateral ureteral obstruction model. J Am Soc Nephrol 17: 2474-2483. (Pubitemid 44300963)
34. Hirokoshi K, Maeshima Y, Kobayashi K, Matsuura E, Sugiyama H, et al. (2007) Elevated serum sFlt-1/Ang-2 ratio in women with preeclampsia. Nephron Clinical practice 106: c43-50. (Pubitemid 46701512)
35. Mallamaci F, Benedetto FA, Tripepi G, Cutrupi S, Pizzini P, et al. (2008) Vascular endothelial growth factor, left ventricular dysfunction and mortality in hemodialysis patients. J Hypertens 26: 1875-1882.
36. Guo Q, Carrero JJ, Yu X, Barany P, Qureshi AR, et al. (2009) Associations of VEGF and its receptors sVEGFR-1 and -2 with cardiovascular disease and survival in prevalent haemodialysis patients. Nephrol Dial Transplant 24: 3468-3473.
37. Futrakul N, Butthep P, Futrakul P (2008) Altered vascular homeostasis in chronic kidney disease. Clin Hemorheol Microcirc 38: 201-207. (Pubitemid 351185407)
38. Shulman K, Rosen S, Tognazzi K, Manseau EJ, Brown LF (1996) Expression of vascular permeability factor (VPF/VEGF) is altered in many glomerular diseases. J Am Soc Nephrol 7: 661-666. (Pubitemid 27465997)
39. Hohenstein B, Colin M, Foellmer C, Amann KU, Brekken RA, et al. (2010) Autocrine VEGF-VEGF-R loop on podocytes during glomerulonephritis in humans. Nephrol Dial Transplant 25: 3170-3180.
40. Miyazaki Y, Kosaka T, Mikami S, Kikuchi E, Tanaka N, et al. (2012) The prognostic significance of vasohibin-1 expression in patients with upper urinary tract urothelial carcinoma. Clin Cancer Res 18: 4145-4153.
41. Wang Q, Tian X, Zhang C (2012) Upregulation of vasohibin-1 expression with angiogenesis and poor prognosis of hepatocellular carcinoma after curative surgery. Med Oncol 29: 2727-2736.
42. Yoshinaga K, Ito K, Moriya T, Nagase S, Takano T, et al. (2008) Expression of vasohibin as a novel endothelium-derived angiogenesis inhibitor in endometrial cancer. Cancer Sci 99: 914-919. (Pubitemid 351997593)
43. Tamaki K, Moriya T, Sato Y, Ishida T, Maruo Y, et al. (2009) Vasohibin-1 in human breast carcinoma: a potential negative feedback regulator of angiogenesis. Cancer Sci 100: 88-94.
44. Tamaki K, Sasano H, Maruo Y, Takahashi Y, Miyashita M, et al. (2010) Vasohibin-1 as a potential predictor of aggressive behavior of ductal carcinoma in situ of the breast. Cancer Sci 101: 1051-1058.
45. Yoshinaga K, Ito K, Moriya T, Nagase S, Takano T, et al. (2011) Roles of intrinsic angiogenesis inhibitor, vasohibin, in cervical carcinomas. Cancer Sci 102: 446-451.
46. Hosaka T, Kimura H, Heishi T, Suzuki Y, Miyashita H, et al. (2009) Vasohibin-1 expression in endothelium of tumor blood vessels regulates angiogenesis. Am J Pathol 175: 430-439.
47. Li D, Zhou K, Wang S, Shi Z, Yang Z (2010) Recombinant adenovirus encoding vasohibin prevents tumor angiogenesis and inhibits tumor growth. Cancer Sci 101: 448-452.
48. Heishi T, Hosaka T, Suzuki Y, Miyashita H, Oike Y, et al. (2010) Endogenous angiogenesis inhibitor vasohibin1 exhibits broad-spectrum antilymphangiogenic activity and suppresses lymph node metastasis. Am J Pathol 176: 1950-1958.
49. Watanabe T, Okada Y, Hoshikawa Y, Eba S, Notsuda H, et al. (2012) A potent anti-angiogenic factor, vasohibin-1, ameliorates experimental bronchiolitis obliterans. Transplant Proc 44: 1155-1157.
50. Horio M, Imai E, Yasuda Y, Watanabe T, Matsuo S (2010) Modification of the CKD epidemiology collaboration (CKD-EPI) equation for Japanese: accuracy and use for population estimates. Am J Kidney Dis 56: 32-38.